Angioimmunoblastic T-cell lymphoma
MONDO:0004977A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites. The clinical course is typically aggressive.
Also known as: AILD, AILT, T-cell lymphoma, AILD type, angioimmunoblastic T-cell lymphoma, angioimmunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy type T-cell lymphoma, angioimmunoblastic lymphadenopathy with Dysproteinemia, immunoblastic lymphadenopathy
1986 clinical trials for this condition and its sub-types, 58 tagged with Angioimmunoblastic T-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug combo shows promise for rare blood cancer in early trial
Disease control CompletedThis study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …
Phase 1/2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill shows promise for rare blood cancer in Late-Stage trial
Disease control CompletedThis phase 3 study tested an oral drug called azacitidine (CC-486) against standard treatments in 93 adults with a rare T-cell lymphoma that had relapsed or stopped responding. The main goal was to see if the drug could delay cancer progression or death. Participants were randoml…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested an oral chemotherapy drug, azacitidine, against standard treatments in 86 patients with a rare type of T-cell lymphoma that had returned or not responded to prior therapy. The main goal was to see if the oral drug could delay cancer progression. The stud…
Phase 3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Phase 2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug candidate BR101801 tested in advanced blood cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …
Phase 1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:53 UTC